FDA grants breakthrough RMAT designation to United Therapeutics’ bioengineered liver assist product
United Therapeutics (NASDAQ:UTHR), a leader in regenerative medicine and organ manufacturing, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational miroliverELAP®.










